The ULT1 and ULT2 patents (available e.g. from http://www.epo.org as WO 2017/095319 and WO 2017/131576, respectively) are open for out-licensing to partners for development to registration and marketing. Initial development as orphan drugs will speed up development.
Further new compounds active against MDR bacteria and new compounds active against fungi have been identified and will be patented (e.g. ULT3) and available for licensing.
A large and growing library of fractions with metabolites from microorganisms is available for screening in assays of medical interest. More than 10.000 fractions are collected annually and this number can be substantially expanded.